The Newborn Metabolic Screening Market to Witness Invigorating Trends

The Newborn Metabolic Screening Market is there to witness remarkable growth in the forecast period. The existing scenario implies the consumerization of healthcare. In other words, technology is relieving the hospital staff from providing an appropriate level of the care needed, that too, in a better way. Data-driven diagnosis has seen the light of the day in wake of habits and requirements of smartphone-oriented patients. This would be the future of the healthcare vertical.

Increasing birth rates across the world are expected to drive demand for newborn metabolic screening, as the risk of galactosemia, sickle cell disease, maple syrup urine disease, and cystic fibrosis is higher among infants. Various countries are implementing screening for metabolic diseases in newborns as a part of their immunization programs. To remain competitive and ensure a robust product pipeline, leading companies continue to identify potential assets through pilot screening programs, which typically have limited resources to see projects through the market.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.persistencemarketresearch.com/samples/31998

According to a latest report published by Persistence Market Research, the global newborn metabolic screening market was valued around US$ 247 Mn in 2020, and is expected to witness an impressive CAGR of over 9% during the forecast period (2020 – 2030).

 Key Takeaways from Market Study  

Sickle cell disease is expected to contribute more than 30% of revenue share to the market.
By sample, blood testing held the highest market share in 2019 due to efficient diagnostic results.
Europe holds a significant share of over 30% in the global newborn metabolic screening market.
Leading manufacturers are focused on strengthening their product portfolios and regional expansion through collaborations.
Hospitals are expected to hold significant market share, due to high number of screening programs being arranged in collaboration with hospitals.
The COVID-19 outbreak has had a negative impact on the market, as short-term lockdowns disturbed the production and supply chain of kits.
The market in the U.S is projected to expand at a CAGR of close to 10% through 2030.
The U.K market has a share of more than 17% in Europe, and is expected to progress at a CAGR of more than 12% over the next ten years.

“Increasing prevalence of new born metabolic diseases and rising adoption of related screening program will boost the global market,” says an analyst of Persistence Market Research.

Get a Customized Scope to Match Your Need Ask an Expert- sales@persistencemarketresearch.com

Companies
PerkinElmer
Bio-Rad Laboratories
Trivitron Healthcare Private Limited
BioMedomics, Inc.
Luminex Corporation
MP BIOMEDICALS
Synergy Medical Systems LLP
Agilent Technologies, Inc
Thermo Fisher Scientific, Inc
Zivak Technologies

Collaborations & Acquisitions Key Strategies amongst Market Players

Leading players in the newborn metabolic screening landscape are focusing on improving their product portfolios through partnerships and acquisitions. Various players are also focusing on regulatory approvals and innovative product launches.

On October 05, 2020, PerkinElmer announced CE-IVD approval of the EONIS™ newborn screening assay.
In October 2018, Trivitron’s Labsystems Diagnostics launched high quality newborn screening panels.
On September 3, 2020, Sickle SCAN® was approved by the Department of Health in Australia.

For in-depth competitive analysis, buy now @ https://www.persistencemarketresearch.com/checkout/31998

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the newborn metabolic screening market in its latest study, presenting historical demand assessment of 2015 – 2019 and projections for 2020 – 2030, on the basis of test (galactosemia, sickle cell disease, cystic fibrosis, toxoplasmosis, (PKU), methylmalonic acidemia, maple syrup urine disease (MSUD), tyrosinemia, citrullinemia, and Medium Chain Acyl CoA Dehydrogenase (MCAD) Deficiency), sample (blood and urine), and end user (diagnostic laboratories, specialty clinics, and hospitals), across seven key regions of the world.

For critical insights, request for methodology @ https://www.persistencemarketresearch.com/methodology/31998

Complete Report Details@ https://www.persistencemarketresearch.com/market-research/newborn-metabolic-screening-market.asp

Contact us:
305 Broadway, 7th Floor
New York City, NY 10007 United States
Ph.no. +1-646-568-7751
E-mail id- sales@persistencemarketresearch.com
Website: https://www.persistencemarketresearch.com

About us-
Business intelligence is the foundation of every business model employed by Persistence Market Research. Multi-dimensional sources are being put to work, which include big data, customer experience analytics, and real-time data collection. Thus, working on “micros” by Persistence Market Research helps companies overcome their “macro” business challenges.

This release was published on openPR.